Last updated: February 11, 2021
Sponsor: University Hospital, Bordeaux
Overall Status: Active - Recruiting
Phase
N/A
Condition
Drugs
Treatment
N/AClinical Study ID
NCT03583749
CHUBX 2017/37
Ages > 65 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Aged over 65
- To receive ceftriaxone (1g daily) or amoxicillin-clavulanate (1g/0.2g every 8h) orpiperacillin-tazobactam (4g/0.5g every 8h) by SC or IV infusion (30-60minutes) atsteady state (48h, 24h and 24h respectively)
- Free, written and informed consent signed by the participant or by a proxy in case ofdelirium
Exclusion
Exclusion Criteria:
- criteria for legislation (justice protection, subject participating to anotherresearch including a period of exclusion)
- previous inclusion in this study
Study Design
Total Participants: 150
Study Start date:
August 07, 2019
Estimated Completion Date:
September 05, 2021
Study Description
Connect with a study center
CHU de Bordeaux
Bordeaux, 33000
FranceActive - Recruiting
Hospital Métropole Savoie
Chambéry, 73000
FranceActive - Recruiting
CHU de Grenoble Alpes
Grenoble, 38700
FranceActive - Recruiting
Hospices Civils de Lyon
Lyon, 69000
FranceActive - Recruiting
University Hospital, Poitiers
Poitiers, 86021
FranceActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.